Australia has expanded access to CSL Seqirus' influenza vaccine, FLUAD, with approval now extended to people aged 50 and over, a move health experts say reflects the growing risk of serious flu complications beginning in midlife.
CSL Seqirus' adjuvanted flu vaccine approval extended to Australians aged 50 and over
March 15, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
Algorae names Nasdaq pharmaceutical chairman to strengthen board
July 15, 2026 - - Australian Biotech -
Starpharma raises $32 Million to advance dendrimer cancer programs
July 15, 2026 - - Australian Biotech -
Minister recommits to keeping MS medicines on the PBS while awaiting formal advice
July 15, 2026 - - Latest News -
Budget outlook now hangs on disability savings, but what about pharmaceuticals
July 15, 2026 - - Latest News -
Australian partnership advances gene therapy for Retinitis Pigmentosa
July 15, 2026 - - Latest News -
Patients move to reclaim access agenda ahead of sector negotiations
July 15, 2026 - - Latest News -
An opportunity to become a global destination for paediatric oncology trials
July 15, 2026 - - Latest News

